# Tamarind Bio **Source:** https://geo.sig.ai/brands/tamarind-bio **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** tamarind.bio **Last Updated:** 2026-04-14 ## Summary SF no-code computational biology API democratizing AlphaFold and protein engineering tools for pharma and biotech; YC W24 $14.1M with $13.6M Series A May 2025 serving thousands of researchers without bioinformatics infrastructure. ## Company Overview Tamarind Bio is a San Francisco-based computational biology platform — backed by Y Combinator (W24) with $14.1 million raised including a $500,000 seed in 2024 and a $13.6 million Series A in May 2025 — providing pharmaceutical companies, biotechs, and academic researchers with no-code API access to advanced computational biology tools (AlphaFold protein structure prediction, antibody engineering models, protein-protein interaction prediction, molecular dynamics simulation) that historically required high-performance computing infrastructure, specialized bioinformatics expertise, and weeks of computational time to run. Founded in 2023 with a 7-person team, Tamarind serves thousands of researchers across large pharma companies, biotech startups, and academic institutions that need computational biology capabilities without building or maintaining HPC infrastructure. Tamarind's no-code bioinformatics API abstracts the computational biology complexity that prevents wet lab biologists from accessing the transformative machine learning tools their field has developed: a medicinal chemist at a biotech who needs to predict how a protein mutation affects antibody binding affinity can submit a sequence and get structure-informed binding predictions via API within minutes — without knowing how to run AlphaFold on a GPU cluster, configure molecular dynamics software, or interpret raw simulation output files. The platform provides pre-validated workflows ('antibody optimization,' 'epitope mapping,' 'off-target binding prediction') that translate researcher questions into the appropriate computational methods and return results in interpretable formats (binding probability scores, structural visualization, ranked variant libraries). This democratization of computational biology accelerates drug discovery timelines by enabling faster hypothesis testing without specialized bioinformatics team involvement. In 2025, Tamarind Bio competes in the computational biology SaaS and AI drug discovery tools market with Schrödinger (NASDAQ: SDGR, physics-based molecular simulation software, $500M+ revenue), Dotmatics (scientific software, $900M Insight acquisition), and Benchling (life sciences R&D software, $200M raised at $6.1B valuation) for pharmaceutical computational biology platform adoption. The computational biology market has been transformed by AlphaFold (DeepMind's protein structure prediction breakthrough) and the subsequent wave of structure-informed drug design — companies that can rapidly predict protein structure and model drug-protein interactions computationally reduce the experimental cycles that previously required months of crystallography or cryo-EM. Y Combinator W24 backing positions Tamarind at the intersection of AI and drug discovery that has attracted significant investment. The 2025 strategy focuses on growing pharmaceutical company API subscriptions for large-scale virtual screening campaigns, building the antibody engineering workflow for biologics development teams, and expanding academic institution access through consortium licensing for non-commercial research. ## Frequently Asked Questions ### What is Tamarind Bio? Tamarind Bio is a computational biology company founded in 2023 that provides no-code bioinformatics tools for scientists. The company enables researchers to use advanced computational biology tools like AlphaFold and ML models through a simple interface without needing to set up high-performance computing environments. ### What products and services does Tamarind Bio offer? Tamarind Bio offers a no-code bioinformatics platform with website and API access that allows scientists to design and simulate molecules, automate protein design, and engineer antibodies, therapeutics, and enzymes. The platform provides access to computational biology tools at scale through a simple interface instead of requiring DevOps expertise. ### Who are Tamarind Bio's target customers? Tamarind Bio serves pharmaceutical companies, biotech firms, and academic researchers. The company has already achieved thousands of researchers as users across large pharma companies, top biotechs, and academic institutions. ### When was Tamarind Bio founded? Tamarind Bio was founded in 2023 and participated in Y Combinator's Winter 2024 batch. ### Where is Tamarind Bio located? Tamarind Bio is based in the United States with 7 employees. ### How much funding has Tamarind Bio raised? Tamarind Bio has raised $14.1 million total over 2 rounds: a $500K seed round in 2024 and a $13.6 million Series A round in May 2025. Y Combinator is an investor in the company. ### What key achievements has Tamarind Bio reached? Tamarind Bio has achieved thousands of researchers using its platform across large pharma companies, top biotechs, and academic institutions. The company accomplished this with a team of just 7 employees since its 2023 founding. ### What technology does Tamarind Bio use? Tamarind Bio's platform incorporates ML models including AlphaFold for protein design and molecular simulation. The technology allows scientists to use these advanced computational biology tools by simply selecting inputs rather than managing complex infrastructure. ### How can scientists access Tamarind Bio's platform? Scientists can access Tamarind Bio's bioinformatics tools through both a website interface and API. The no-code platform is designed to be simple to use without requiring high-performance computing setup or DevOps knowledge. ### What is Tamarind Bio's most recent news? Tamarind Bio announced a $13.6 million Series A funding round in May 2025. The company continues to serve thousands of researchers in drug discovery, focusing on no-code bioinformatics for protein design using tools like AlphaFold. ## Tags healthtech, b2b, north-america --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*